PT-141 (Bremelanotide)
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, also studied for broader sexual dysfunction.
What is PT-141 (Bremelanotide)?
PT-141, known pharmaceutically as Bremelanotide (brand name Vyleesi), is an FDA-approved peptide medication for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through the melanocortin system in the brain rather than through hormonal or vascular mechanisms, representing a novel approach to sexual dysfunction treatment. Phase 3 RECONNECT trials demonstrated significant improvements in sexual desire and reduced distress. Unlike PDE5 inhibitors (like Viagra), PT-141 acts centrally on desire rather than peripherally on blood flow.
What PT-141 (Bremelanotide) Is Investigated For
PT-141 (bremelanotide, Vyleesi) is an FDA-approved melanocortin-4 receptor agonist for hypoactive sexual desire disorder in premenopausal women, and is also widely used off-label for female sexual dysfunction more broadly and for male erectile dysfunction. The strongest evidence is for its labeled HSDD indication: the two pivotal Phase 3 RECONNECT trials (~1,250 women, 24 weeks) demonstrated significant improvements in sexual desire scores and reduced distress versus placebo, supported by long-term open-label extension data at 52 weeks, leading to FDA approval in June 2019. Trial effect sizes have been modest and have drawn some re-analysis critique. The historical male ED evidence base is older (intranasal PT-141 era Phase 1–2 work), but Palatin is now running a Phase 2/3 program of bremelanotide co-formulated with a PDE5 inhibitor specifically for men who do not respond to PDE5i monotherapy — Phase 2 initiated in 2024 and topline Phase 3 data is targeted for H1 2026, which will be the first rigorous modern readout for the male indication. Nausea — roughly 40% of users in pivotal trials — is the dominant tolerability issue, and transient BP elevation plus occasional hyperpigmentation are documented. Compounded bremelanotide differs from approved Vyleesi in manufacturing quality and regulatory status, and the two should not be treated as interchangeable.
History & Discovery
PT-141 — bremelanotide — emerged from an unusual path: the melanocortin tanning-agent program that produced Melanotan II. Researchers at the University of Arizona in the 1980s and 1990s, led by Mac Hadley and Victor Hruby, were developing alpha-MSH analogs intended to induce melanogenesis as a prospective skin-cancer prevention strategy. In the course of that work, it became clear that several of the peptides produced unexpected central effects, including sexual arousal — a finding recorded in the often-repeated anecdote of an early self-experiment by one of the Arizona team. Palatin Technologies licensed the chemistry and, working from Melanotan II, developed a more selective cyclic heptapeptide — bremelanotide — with relatively reduced melanocortin-1 receptor activity (less pigmentary effect) and preserved MC3R/MC4R activity (preserved sexual function effect). Early intranasal development for erectile dysfunction in men ran through the mid-2000s before Palatin shifted focus to premenopausal women with hypoactive sexual desire disorder, reformulated as a subcutaneous auto-injector, and partnered with AMAG Pharmaceuticals. The pivotal Phase 3 RECONNECT program enrolled ~1,250 women and demonstrated significant improvement in sexual desire scores and reduced distress versus placebo. The FDA approved Vyleesi in June 2019 for premenopausal HSDD not due to a coexisting medical or psychiatric condition, relationship problems, or medication. Palatin reacquired full rights from AMAG in 2023 and then sold the worldwide Vyleesi rights to Cosette Pharmaceuticals in a deal announced December 20, 2023 and closed January 3, 2024 (up to $171M; $12M upfront plus $159M in milestones). Cosette now commercializes Vyleesi, while Palatin has continued developing bremelanotide for other indications — notably a Phase 2/3 co-formulation with a PDE5 inhibitor for men with erectile dysfunction who do not respond to PDE5i monotherapy (Phase 2 began in 2024, Phase 3 recruitment planned for H2 2025, topline readout targeted for H1 2026) and a Phase 2 MC4R-agonist obesity program that met its primary endpoint in March 2025 when bremelanotide co-administered with tirzepatide halted weight regain in a GLP-1/GIP maintenance setting. Throughout this regulatory history, a parallel track of unregulated use developed — particularly in men seeking a centrally-acting alternative to PDE5 inhibitors, and via the research-chemical and wellness-clinic markets. That off-label use is common but sits entirely outside the FDA-approved indication.
How It Works
PT-141 works in the brain's desire centers rather than the body's plumbing. It activates melanocortin receptors that influence sexual desire and arousal at the neurological level, which is why it works differently from drugs like Viagra.
PT-141 (Bremelanotide) is a cyclic heptapeptide that acts as an agonist at melanocortin-4 receptors (MC4R) in the central nervous system. MC4R activation in the hypothalamus and limbic system — including the medial preoptic area and paraventricular nucleus — modulates dopaminergic and oxytocinergic pathways involved in sexual desire and arousal. Unlike PDE5 inhibitors, it acts centrally on desire rather than peripherally on vascular function.
Evidence Snapshot
Human Clinical Evidence
Strong. Two pivotal Phase 3 clinical trials (RECONNECT) led to FDA approval. Over 1,200 patients studied.
Animal / Preclinical
Extensive. Well-characterized in animal models of sexual behavior.
Mechanistic Rationale
Strong. MC4R's role in sexual function is well-established.
Research Gaps & Open Questions
What the current literature has not yet settled about PT-141 (Bremelanotide):
- 01Efficacy in postmenopausal women — Vyleesi is approved only for premenopausal HSDD; whether postmenopausal women experience comparable effect is not established in adequately powered trials.
- 02Efficacy in men — historical male trial data (intranasal PT-141 era, SC Phase 1–2 work) is older, but Palatin's current Phase 2/3 program of bremelanotide co-formulated with a PDE5 inhibitor in PDE5i non-responders is expected to report Phase 3 topline data in H1 2026. That readout will be the first modern rigorous evidence for the male indication and will materially update where this gap stands.
- 03Long-term cumulative safety — the RECONNECT open-label extension provided 52-week data, but beyond that, cumulative cardiovascular, pigmentary, and melanocortin-system effects over years of use are not well characterized.
- 04Compounded vs. approved product equivalence — potency, purity, and sterility of compounded bremelanotide are not standardized, and direct comparative clinical data between compounded product and Vyleesi are absent.
- 05Responder identification — trial effect sizes have been modest and variable across subgroups; better predictors of who responds meaningfully would sharpen clinical decision-making.
- 06Central melanocortin biology — MC3R vs. MC4R contributions to the desire effect remain incompletely parsed, which matters for next-generation melanocortin agonists in development.
- 07Obesity — Palatin reported a positive Phase 2 readout in March 2025 showing bremelanotide co-administered with tirzepatide halted weight regain in a GLP-1/GIP maintenance setting (MC4R-based appetite suppression complementing incretin-driven weight loss). Whether next-generation MC4R agonists (Palatin filed IND applications Q4 2025) translate this signal into Phase 3 efficacy is the open question.
Forms & Administration
FDA-approved as a subcutaneous auto-injector (Vyleesi). Administered at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, 8 doses per month. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The FDA-approved Vyleesi auto-injector delivers 1.75 mg subcutaneously per dose. In compounded and off-label use, protocols described in wellness clinics and research-chemical contexts range more broadly — commonly 0.5–2 mg per dose, titrated based on tolerability (particularly nausea).
Frequency
Dosing is as-needed before anticipated sexual activity rather than scheduled. Labeling specifies at least 45 minutes before activity, no more than one dose per 24 hours, and no more than 8 doses per month. The 8-doses-per-month cap is based on a balance of safety monitoring data and the trial protocol structure rather than a hard pharmacological ceiling.
Timing Considerations
Time of day
On-demand only. Dose 45 minutes to 2 hours before anticipated sexual activity — there is no daily baseline regimen for this peptide.
Relative to meals
Meal timing is secondary to the activity-timing window. Alcohol co-use is the bigger consideration and is typically discouraged because PT-141's transient blood-pressure rise compounds with alcohol effects.
Relative to exercise
Unrelated to training.
Effect window is roughly 4–8 hours after injection. Tolerance and side effects (nausea, flushing, transient blood-pressure rise) tend to be dose- and frequency-dependent — the approval label caps use at 8 doses per month for a reason.
Cycle Length
Not cycled in the conventional sense. It is an as-needed agent rather than a continuous protocol. Long-term open-label extension data (52 weeks) supports sustained as-needed use within the labeled dose frequency.
Protocol Notes
Timing is the most important practical detail. The 45-minute lead time accounts for subcutaneous absorption and central onset; dosing closer to activity may miss the window, and dosing much earlier does not appear to extend duration meaningfully. Nausea — experienced by roughly 40% of users in the pivotal trials, most common with the first several doses — is the single biggest tolerability issue and a major driver of discontinuation. It typically attenuates with repeated use. Some users find co-administration with an antiemetic or a small food buffer helps; formal guidance does not require it. Transient blood pressure elevation occurs within hours of dosing and resolves within 8–10 hours; the effect is typically modest but is the reason for cardiovascular screening and the 24-hour dose spacing. Hyperpigmentation — darkening of the face, gums, or breasts — occurs in roughly 1% of users at the labeled dosing limits (≤8 doses per month) reflecting residual MC1R activity, but the rate climbs dramatically with off-label high-frequency use: older short daily-dosing studies have reported hyperpigmentation in up to 38.2% of subjects receiving 8–16 consecutive daily doses. Higher baseline pigmentation raises the risk further, and resolution on discontinuation is not confirmed in all cases. This gap between labeled-use and off-label-use rates is the single most important reason to respect the 8-doses-per-month limit. Off-label use in men is common in compounding and clinic practice; dose-ranging in this context is informal and not FDA-sanctioned. The trial evidence supporting use in men is older Phase 1–2 data rather than Phase 3 efficacy studies.
Vyleesi is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use in men, in postmenopausal women, or outside the labeled dosing parameters is off-label. Compounded bremelanotide and research-chemical bremelanotide are not equivalent to the approved Vyleesi auto-injector in either quality control or legal status.
Timeline of Effects
Onset
Subcutaneous bremelanotide produces detectable plasma concentrations within 15–30 minutes and central effects typically begin around 30–45 minutes post-injection, which is the basis for the 45-minute-before-activity labeling. Peak plasma concentration is around 60–90 minutes.
Peak Effect
Subjective arousal effects are typically reported in the 1–3 hour window post-dose. Duration of the arousal effect is described as up to ~8 hours, though most of the usable window is in the first several hours. Desire effects in HSDD trials are measured by monthly score changes over 24 weeks of as-needed use, not per-dose; the trial endpoint is cumulative rather than immediate.
After Discontinuation
Plasma half-life is approximately 2.7 hours. Pharmacological effects of any single dose are essentially cleared within 12–24 hours. There is no rebound or withdrawal effect from discontinuation. Benefits in HSDD accrue over weeks of use and taper accordingly when dosing stops.
Monitoring & Measurement
Bloodwork & Labs
- •Blood pressure (home cuff) — the only routinely useful objective marker; PT-141 can raise systolic 5–10 mmHg for 6–10 hours post-dose
- •Fasting glucose in insulin-resistant users — melanocortin signaling has metabolic adjacencies worth tracking if you're already dysglycemic
Functional & Performance Tests
- •FSFI (Female Sexual Function Index) or IIEF (International Index of Erectile Function) — validated questionnaires that outperform gut-feel tracking for libido and arousal effects
- •Relationship or frequency journal to anchor the subjective scales
When to Test
Blood pressure at baseline and 2 hours post-dose on the first 3–5 administrations. FSFI or IIEF at baseline and after 4–6 dosing events.
Interpretation & Notes
PT-141's effect is primarily subjective, so validated questionnaires (FSFI for women, IIEF for men) are the only credible way to track response with reasonable signal-to-noise. The objective marker worth actively monitoring is blood pressure — home cuff measurement 2 hours post-injection, especially on the first few doses, catches the typical transient systolic rise of 5–10 mmHg. If you're already hypertensive or on BP-lowering medication, flag this to your clinician before starting. There is no reliable bloodwork endpoint for sexual-response effects; this is a central-nervous-system drug working through melanocortin receptors in the brain, not a hormone modulator. No direct-to-consumer lab captures it.
Common Questions
Who PT-141 (Bremelanotide) Is NOT For
- •Uncontrolled hypertension or known cardiovascular disease — bremelanotide produces transient increases in blood pressure and small decreases in heart rate after each dose, which are acceptable in low-risk users but contraindicated in those with poorly controlled BP or established cardiovascular disease.
- •Pregnancy — no adequate safety data and the indication is specifically for premenopausal women managing desire; use during pregnancy is not supported.
- •Known hypersensitivity to bremelanotide or any component of the Vyleesi auto-injector (including compounded-product excipients).
- •Concurrent use of oral naltrexone for alcohol or opioid use disorder — bremelanotide can significantly decrease oral naltrexone absorption, potentially reducing its efficacy.
- •Individuals with risk factors for significant hyperpigmentation (high baseline pigmentation plus planned frequent high-dose use) where cosmetic effect would be an unwelcome outcome — this is a relative rather than absolute contraindication and a counseling point.
- •Use in men and in postmenopausal women is not FDA-approved and sits outside the evidence base for HSDD efficacy; not a contraindication in the strict medical sense but a scope-of-approval constraint worth naming.
Drug & Supplement Interactions
The clinically most relevant documented interaction is with oral naltrexone: bremelanotide significantly reduces its absorption and should be avoided in patients using oral naltrexone for alcohol or opioid use disorder. Injectable extended-release naltrexone (Vivitrol) is affected differently and the clinical implication is less clear. Antihypertensive medications: bremelanotide produces transient BP elevation, which interacts with background antihypertensive regimens in complex ways — in trials, the net effect was typically modest, but in patients with borderline BP control the temporary increase can matter. Users with cardiovascular risk factors should have BP well-controlled before initiating. PDE5 inhibitors (sildenafil, tadalafil) in men: combination use is common in off-label male practice and has been described in older Phase 1–2 trials of intranasal PT-141 plus sildenafil. Because the two agents work through different pathways (central melanocortin vs. peripheral vascular), the pharmacological interaction is not additive in a concerning way, but the combined cardiovascular load warrants clinical oversight. Beyond naltrexone, bremelanotide does not have a large panel of documented pharmacokinetic interactions; it does not meaningfully inhibit or induce cytochrome P450 enzymes at therapeutic doses.
Safety Profile
Common Side Effects
Cautions
- • Nausea is common and can be significant
- • Not for use with certain cardiovascular conditions
- • Maximum 8 doses per month recommended
- • Can cause temporary blood pressure changes
What We Don't Know
Long-term effects of repeated melanocortin receptor activation are being monitored through post-marketing surveillance.
Legal Status
United States
Bremelanotide is FDA-approved as Vyleesi for premenopausal women with acquired, generalized HSDD. Commercial rights passed from AMAG Pharmaceuticals to Palatin Technologies in 2023, and Palatin sold worldwide Vyleesi rights to Cosette Pharmaceuticals in January 2024 (up to $171M) — Cosette is now the commercial owner. Vyleesi is a prescription-only medication with Orange Book patent protection extending to 2041. Compounding pharmacies sell compounded bremelanotide under various arrangements; because an FDA-approved reference product exists, compounding is more tightly restricted than for peptides with no approved analog. The April 2026 FDA Category 2 update (which removed 12 peptides including BPC-157 and TB-500 from Category 2) did not change bremelanotide's compounding posture. Research-chemical bremelanotide sold online is not authorized for human use. It is not a controlled substance.
International
Approval is limited relative to the US. Vyleesi is not broadly approved across the EU or UK; specific-country regulatory status varies, and many jurisdictions have no approved product. Australian TGA has not approved bremelanotide. Personal importation rules vary; in several jurisdictions, compounded or research-chemical bremelanotide is legally ambiguous to outright prohibited.
Sports & Competition
Bremelanotide is not specifically listed on the WADA Prohibited List and is not classified as a performance-enhancing drug. Competitive athletes should nonetheless verify that any compounded or research-sourced product is not cross-contaminated with prohibited substances — an ongoing issue with compounded peptides generally.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
PT-141 is FDA-approved for men with erectile dysfunction.
Reality
It is not. Vyleesi is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. Use in men is off-label. Earlier intranasal PT-141 development targeted male ED but was not carried through to approval, and no bremelanotide product is approved for any male indication.
Myth
PT-141 works like Viagra — by increasing blood flow.
Reality
PT-141 works centrally via melanocortin-4 receptors in the hypothalamus to affect desire and arousal. PDE5 inhibitors like Viagra work peripherally via cGMP and smooth-muscle relaxation to affect erection. The mechanisms are fundamentally different. PT-141 does not reliably produce erections on demand the way PDE5 inhibitors do.
Myth
Nausea with PT-141 means you took too much.
Reality
Nausea is the single most common side effect and affected roughly 40% of users in pivotal trials, most often with the first several doses and typically attenuating over time. It reflects central melanocortin activation rather than overdosing per se. Some users never develop tolerance; that is a reason for discontinuation rather than a dosing error.
Myth
Compounded bremelanotide is the same as Vyleesi.
Reality
They share a peptide sequence but differ in manufacturing quality control, sterility assurance, device presentation, and regulatory status. Compounded product is also outside the FDA-approved indication. Treating the two as interchangeable is a category error.
Myth
PT-141 is a controlled substance.
Reality
It is not. It is a prescription-only medication (as Vyleesi) in the US, but not scheduled under the Controlled Substances Act. That does not make compounded or research-chemical product legally safe to purchase or use outside a legitimate prescribing relationship.
Published Research
36 studiesFemale Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials
Safety Profile of Bremelanotide Across the Clinical Development Program
Comprehensive safety analysis pooling data from the entire bremelanotide clinical development program, characterizing the nausea rate (~40%), transient blood pressure changes, and skin hyperpigmentation that informed the FDA labeling and dosing limits.
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
Bremelanotide
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'"
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Open-label extension study following RECONNECT participants for up to 12 months, confirming sustained efficacy and an acceptable long-term safety profile with no new safety signals — critical data for the FDA approval package.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
The two pivotal RECONNECT Phase 3 trials (n=1,247) that formed the basis for FDA approval, demonstrating bremelanotide significantly increased sexual desire and reduced distress in premenopausal women with HSDD compared to placebo over 24 weeks.
Bremelanotide: First Approval
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder
Bremelanotide
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response
Gateways to clinical trials
PT-141 Palatin
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Seminal Phase 1 RCT establishing proof of concept for melanocortin-mediated sexual function, showing intranasal PT-141 induced erections in both healthy men and ED patients — the first demonstration that a centrally-acting melanocortin agonist could treat sexual dysfunction.
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Popular Stacks Including PT-141 (Bremelanotide)
Quick Facts
- Class
- Melanocortin Receptor Agonist
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 36PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.